Related Experiment Video
Updated: Dec 9, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Soft-tissue Sarcoma of the Hand: Patient Characteristics, Treatment, and Oncologic Outcomes
Jonathan Lans1, Kai-Lou C Yue, René M Castelein
1From the Department of Orthopaedic Surgery, Hand and Upper Extremity Service, Massachusetts General Hospital, Harvard Medical School, Yawkey Center, Boston, MA (Dr. Lans and Dr. Chen), the Department of Orthopaedic Surgery, Orthopaedic Oncology Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA (Ms. Yue and Dr. Lozano Calderon), the Department of Orthopedic Surgery, University Medical Center Utrecht, Utrecht, the Netherlands (Dr. Castelein), and the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Yawkey Center, Boston, MA (Dr. Suster and Dr. Nielsen).
Introduction:
The aim of this study was to describe patient characteristics, treatment, and oncologic outcomes of soft-tissue sarcomas (STSs) of the hand.
Methods:
Sixty-nine STSs of the hand in adult patients treated at a tertiary referral center were retrospectively included. We describe patient and tumor characteristics along with oncologic outcomes.
Results:
Epithelioid sarcoma (23%) was the most common histologic subtype, followed by synovial sarcoma (15%). Of all tumors, 17 (25%) were grade I, 22 (32%) were grade II, and 30 (44%) were grade III. The 5-year disease-free survival for epithelioid sarcomas was 75% with a disease survival of 100%, along with a metastatic rate of 15%. Of the patients with a synovial sarcoma, 40% developed metastases, and the 5-year disease-free survival was 68% and the 5-year disease survival was 73%.
Conclusion:
Hand STSs are aggressive tumors with a high metastatic potential. Even with adequate oncologic treatment, long-term clinical follow-up (10 years) in these tumors is advised. The treating surgical oncologist should not be deceived by their smaller size.
Related Concept Videos
Treatment Resistant Cancers
Cancer Survival Analysis

